News >

Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes

Jason Harris
Published: Wednesday, Aug 29, 2018

Banu K. Arun, MD

Banu K. Arun, MD

Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.

 during the meeting, Arun discussed the challenge of treating these patients, the value of genotyping, and what she hopes to see in future trial results.

OncLive: What were some key points of your lecture?

Arun: As you know, women with germline BRCA mutations mostly have high-grade cancers, especially BRCA1-related breast cancers. They have more triple-negative disease and more aggressive cancers. Recently, new approaches have been evaluated in these patients, including PARP inhibitors. I reviewed 2 very recently reported phase III studies looking at singleagent PARP inhibitors versus physician’s choice of therapy.

We don’t have any predictive biomarkers of response and we are just now beginning to do targeted therapy with immunotherapy and immunomodulation targeting the PI3K/AKT/mTOR pathway. We targeting the androgen receptor in TNBC. I reviewed the principles of these approaches but none of them are standard of care yet, unfortunately. We are still treating TNBC with standard therapies.

Has genotyping become more important since LOTUS was reported?

The LOTUS trial looked at an AKT inhibitor plus chemotherapy versus chemotherapy alone. The combination was significantly better than single-agent chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication